Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer

Ariake, Kyohei; Motoi, Fuyuhiko; Mizuma, Masamichi; Ohtsuka, Hideo; Hayashi, Hiroki; Nakagawa, Kazuhiko; Hata, Tatsuo; Mitachi, Katsutaka; Naitoh, Takeshi; Kamei, Takashi; Unno, Michiaki

doi:10.1007/s00595-019-01842-5

Cited by 5 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy of chemotherapy differs among individual patients because tumor sensitivity to anticancer agents varies widely (17)(18)(19). The pathological response to NAC, as confirmed by examining resected specimens, can serve as a kind of "in vivo chemosensitivity test".…”

Section: Discussionmentioning

confidence: 99%

“…The pathological response to NAC, as confirmed by examining resected specimens, can serve as a kind of "in vivo chemosensitivity test". The clinical efficacy of in vitro chemosensitivity tests using cancer cells from resected specimens of various malignancies, such as gastric, colorectal, and pancreatic cancer, has been reported (17)(18)(19). Ariake et al conducted a collagen gel droplet-embedded culture drug sensitivity test to evaluate the efficacy of 5- fluorouracil (FU)-based S-1 adjuvant chemotherapy in 22 pancreatic cancer patients and demonstrated that 5-FUsensitive patients had a better recurrence-free survival outcome than 5-FU-resistant patients (19).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

Background/Aim: An association between the pathological response to neoadjuvant chemotherapy (NAC) and the efficacy of adjuvant chemotherapy (AC) in patients with pancreatic ductal adenocarcinoma (PDAC) remains unknown. Patients and Methods: A total of 121 patients with PDAC who underwent a pancreatectomy between January 2013 and March 2020 were divided into two groups: an upfront surgery (UFS) group (n=42), and an NAC (gemcitabine plus S-1) group (n=79). In the NAC group, the pathological response was evaluated using the Evans classification. Results: The overall survival was significantly higher in patients with an AC relative dose intensity (RDI) ≥80% than in patients with an AC RDI <80% in the UFS, NAC-Evans IIa, and NAC-Evans IIb+III groups. However, this difference was not observed in the NAC-Evans I group. Conclusion: AC is preferable for patients with NAC-Evans IIa or IIb+III, but more effective AC regimens may be needed for NAC-Evans I patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma

et al. 2021

View full text Add to dashboard Cite

show abstract

A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors

Goto,

Ohtsu,

Ito

et al. 2023

Human Cell

View full text Add to dashboard Cite

Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer

Mitachi

Ariake

Shima

et al. 2021

Sci Rep

Self Cite

View full text Add to dashboard Cite

The collagen gel droplet-embedded drug sensitivity test (CD-DST) was revealed to be useful for predicting the effect of S-1 adjuvant chemotherapy for pancreatic ductal adenocarcinoma (PDAC). However, collection of an adequate number of PDAC cells is difficult due to the surrounding fibroblasts. Thus, the aim of this study was to discover novel biomarkers to predict chemosensitivity based on the CD-DST results. Proteomics analysis was performed using liquid chromatography tandem mass spectrometry (LC–MS/MS). Candidate proteins were validated in patients with 5-FU CD-DST results via immunohistochemistry (IHC). The relationships between the candidate proteins and the effect of the adjuvant S-1 were investigated via IHC. Among the 2696 proteins extracted by LC–MS/MS, C1TC and SAHH could accurately predict the CD-DST results. Recurrence-free survival (RFS) was significantly improved in the IHC-positive group compared with the IHC-negative group in both factors. The negative group did not show a significant difference from the group that did not receive S-1. The double-positive group was associated with significantly prolonged RFS compared to the no adjuvant chemotherapy group. C1TC and SAHH have been shown to be useful biomarkers for predicting 5-FU sensitivity as a substitute for the CD-DST in adjuvant chemotherapy for PDAC.

show abstract

Collagen gel droplet-embedded culture drug sensitivity test (CD-DST) predicts the effect of adjuvant chemotherapy on pancreatic cancer

Cited by 5 publications

References 17 publications

Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma

Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma

A short-term three dimensional culture-based drug sensitivity test is feasible for malignant bone tumors

Novel candidate factors predicting the effect of S-1 adjuvant chemotherapy of pancreatic cancer

Contact Info

Product

Resources

About